Diabetes Risk Evaluation and Management Tele-monitoring Study (DREAM-Tel)
NCT ID: NCT00325624
Last Updated: 2012-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2006-11-30
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples
NCT00741702
Diabetes Nutrition Education and Healthy Food Resource for AIANs With T2D
NCT06077162
Promoting Blood Pressure Control and Cholesterol Reduction to Prevent Major Complications in Persons With Diabetes
NCT00210262
Electronically Connected Health Coaching in Type 2 Diabetes
NCT02036892
Transformation of Indigenous Primary Healthcare Delivery
NCT02234973
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Despite current Clinical Practice Guidelines and evidence-based practice by the medical community, including family physicians and the Home Care team, blood glucose control in general and in the First Nations community specifically is not meeting targets. Poor control of blood glucose in type 2 diabetes dramatically increases the risk of heart disease, stroke, vascular limb loss, blindness, kidney disease and the need for dialysis. Control of blood glucose levels prevents these complications. Additionally, the intensification of diabetes control, including the initiation of insulin, is not easily done during a regular primary care visit. The lack of intensification of diabetes management in people with poorly controlled diabetes has been referred to as 'clinical inertia'. While subjects referred to specialists have somewhat better control of diabetes, more than 50% still failed to have intensification of diabetes management within four months of a lab report showing a high level of A1c. Multidisciplinary care can overcome clinical inertia, even in difficult practice settings. Finally, the emerging technology of Bluetooth-enabled devices and secure web-based monitoring logs allows health care providers for the first time to remotely monitor progress providing a higher level of confidence in self blood glucose monitoring (SBGM) and blood pressure results. Based on these facts, the experimental focus of this proposal is on the introduction of a Home Care Team diabetes management program that can provide intensification of diabetes management right in the patient's home, supported by the emerging technology of Bluetooth- enabled devices. The specific aims are designed to provide a comprehensive assessment of the impact of the introduction of this program.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bluetooth-enabled Glucometer
blood glucose information provided to health care providers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be greater than or equal to 18 years of age.
* Written informed consent must be obtained prior to admission to this study.
Exclusion Criteria
* New York Heart Association Stage III-IV congestive heart failure. This will eliminate approximately 2% of people with diabetes based on the Strong Heart Study Data.
* Suspected secondary hypertension due to any cause (e.g. pheochromocytoma,coarction of the aorta or renal insufficiency.)
* Unstable angina, myocardial infarction, or revascularization within the last 3 months.
* Angioedema.
* Cerebrovascular event, including stroke or transient ischemic attack, within the last six months.
* Creatinine \>250 umol/L
* Cerebral Vascular event, including strike or transient ischemic attack, within the last six months.
* Connective tissue disorders (e.g.lupus, rheumatoid arthritis)
* Active hepatic disease as indicated by AST and ALT \>2X the upper limit of normal; serum bilirubin \>1.5X upper limit of normal, or serum albumin \<3.0 gm/dl.
* Severe systemic or malignant disease(which could reasonably be expected to be fatal or life-threatening during the course of the study.)
* Pregnancy. It is expected that some women will want to exit the study to become pregnant (5% of female enrollees).
* Factors suggesting low likelihood of compliance with the protocol (e.g current alcohol abuse, history of unreliability in keeping appointments or taking medications.
* Any medical condition that study physicians believe would interfere with study participation or evaluation of results.
* Mental incapacity and/or cognitive impairment on the part of the patient that would preclude adequate understanding of, or cooperation with, the study protocol.
* Participation in any clinical trial of any investigational medication within 3 months prior to this trial. This is unlikely because clinical trials among First Nations people are rare.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Battlefords Tribal Council Indian Health Services
UNKNOWN
SaskTel
INDUSTRY
Sunnybrook Health Sciences Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sheldon Tobe
Associate Professor of Medicine, University of Toronto
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sheldon W Tobe, MD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
Sunnybrook Health Sciences Centre
George Pylypchuk, MD, FRCP(C)
Role: PRINCIPAL_INVESTIGATOR
University of Saskatchewan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Battleford Tribal Council Indian Health Services
North Battleford, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tobe SW, Wentworth J, Ironstand L, Hartman S, Hoppe J, Whiting J, Kennedy J, McAllister C, Kiss A, Perkins N, Vincent L, Pylypchuk G, Lewanczuk RZ. DreamTel; Diabetes risk evaluation and management tele-monitoring study protocol. BMC Endocr Disord. 2009 May 9;9:13. doi: 10.1186/1472-6823-9-13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.